Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

Nature Biotechnology

Volumn 26, Issue 8, 2008, Pages 925-932

  Junutula, Jagath R ^a   Raab, Helga ^a   Clark, Suzanna ^a   Bhakta, Sunil ^a   Leipold, Douglas D ^a   Weir, Sylvia ^a   Chen, Yvonne ^a   Simpson, Michelle ^a   Tsai, Siao Ping ^a   Dennis, Mark S ^a   Lu, Yanmei ^a   Meng, Y Gloria ^a   Ng, Carl ^a   Yang, Jihong ^a   Lee, Chien C ^a   Duenas, Eileen ^a   Gorrell, Jeffrey ^a   Katta, Viswanatham ^a   Kim, Amy ^a   McDorman, Kevin ^a,b   Flagella, Kelly ^a   Venook, Rayna ^a   Ross, Sarajane ^a   Spencer, Susan D ^a   Lee Wong, Wai ^a   Lowman, Henry B ^a   Vandlen, Richard ^a   Sliwkowski, Mark X ^a   Scheller, Richard H ^a   Polakis, Paul ^a   Mallet, William ^a   more..

^a GENENTECH INC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ANTIGENS; BINDING SITES; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DRUG DELIVERY;

ANTI-TUMOR EFFICACY; ANTIGEN-BINDING; ANTITUMOR EFFECTS; CYNOMOLGUS MONKEYS; CYSTEINE SUBSTITUTIONS; CYTOTOXIC; CYTOTOXIC DRUGS; DRUG CONJUGATES; GENERAL APPROACH; HEAVY CHAINS; HOMOGENOUS COMPOSITION; IN-VIVO; OVARIAN CANCERS; PHAGE DISPLAYS; REACTIVE THIOL GROUPS; SITE-SPECIFIC; SYSTEMIC EFFECTS;

DRUG DOSAGE;

ANTIBODY CONJUGATE; CYSTEINE; CYTOTOXIC AGENT; GEMTUZUMAB OZOGAMICIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MONOMETHYL AURISTATIN E; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG CONJUGATION; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL STUDY; HEAVY CHAIN; IN VIVO STUDY; LIGHT CHAIN; MONKEY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RAT; XENOGRAFT;

MACACA FASCICULARIS; RATTUS;

EID: 49449087300     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1480     Document Type: Article

References (33)

1. Adams, G.P. & Weiner, L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-1157 (2005).
2. Baker, M. Upping the ante on antibodies. Nat. Biotechnol. 23, 1065-1072 (2005).
3. Polakis, P. Arming antibodies for cancer therapy. Curr. Opin. Pharmacol. 5, 382-387 (2005).
4. Wu, A.M. & Senter, P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137-1146 (2005).
5. Lambert, J.M. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol. 5, 543-549 (2005).
6. Chen, Y. et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 67, 4924-4932 (2007).
7. Doronina, S.O. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778-784 (2003).
8. Hamblett, K.J. et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-7070 (2004).
9. Henry, M.D. et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 64, 7995-8001 (2004).
10. Kovtun, Y.V. et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66, 3214-3221 (2006).
11. Liu, C. & Chari, R.V. The development of antibody delivery systems to target cancer with highly potent maytansinoids. Expert Opin. Investig. Drugs 6, 169-172 (1997).
12. Ross, S. et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 62, 2546-2553 (2002).
13. Sanderson, R.J. et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 11, 843-852 (2005).
14. Sun, M.M. et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug. Chem. 16, 1282-1290 (2005).
15. Tassone, P. et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1- oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 64, 4629-4636 (2004).
16. Tolcher, A.W. et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. 21, 211-222 (2003).
17. Doronina, S.O. et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 17, 114-124 (2006).
18. Ma, D. et al. Potent antitumor activity of an auristatin- conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin. Cancer Res. 12, 2591-2596 (2006).
19. Tse, K.F. et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin. Cancer Res. 12, 1373-1382 (2006).
20. Wang, L., Amphlett, G., Blattler, W.A., Lambert, J.M. & Zhang, W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 14, 2436-2446 (2005).
21. Jefferis, R. Structure-function relationships of the IgG subclasses. in The Human IgG Subclasses: Molecular Analysis of Structure, Function and Regulation (ed. Shakib, F.) 93-108 (Pergamon Press, Oxford, 1990).
22. Junutula, J.R. et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Methods 332, 41-52 (2008).
23. Dubowchik, G.M. et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem. 13, 855-869 (2002).
24. Francisco, J.A. et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102, 1458-1465 (2003).
25. Mirsalis, J.C. et al. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance. Cancer Chemother. Pharmacol. 44, 395-402 (1999).
26. McDonagh, C.F. et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng. Des. Sel. 19, 299-307 (2006).
27. Michaelsen, T.E. et al. One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge. Proc. Natl. Acad. Sci. USA 91, 9243-9247 (1994).
28. Romans, D.G., Tilley, C.A., Crookston, M.C., Falk, R.E. & Dorrington, K.J. Conversion of incomplete antibodies to direct agglutinins by mild reduction: evidence for segmental flexibility within the Fc fragment of immunoglobulin G. Proc. Natl. Acad. Sci. USA 74, 2531-2535 (1977).
29. Seegan, G.W., Smith, C.A. & Schumaker, V.N. Changes in quaternary structure of IgG upon reduction of the interheavy-chain disulfide bond. Proc. Natl. Acad. Sci. USA 76, 907-911 (1979).
30. Lyons, A. et al. Site-specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Eng. 3, 703-708 (1990).
31. Stimmel, J.B. et al. Site-specific conjugation on serine right-arrow cysteine variant monoclonal antibodies. J. Biol. Chem. 275, 30445-30450 (2000).
32. Chapman, A.P. et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol. 17, 780-783 (1999).
33. Xiang, T., Lundell, E., Sun, Z. & Liu, H. Structural effect of a recombinant monoclonal antibody on hinge region peptide bond hydrolysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 858, 254-262 (2007).